Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
You may also be interested in...
COVID-19 continues to hinder Abbott’s heart failure and neuromodulation business, but sales of COVID-19 tests drove unprecedented growth in the diagnostics business.
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.